482 Safety and Efficacy of Velaglucerase Alfa in Gaucher Disease Type 1 Patients Previously Treated with Imiglucerase
Gregory A. Grabowski(Cincinnati Children's Hospital Medical Center), E. Crombez(Lexington VA Health Care System), Laurie D. Smith(Children's Mercy Hospital), Atul Mehta(University College London), Ari Zimran(Hebrew University of Jerusalem), Anna Tylki‐Szymańska(Children's Memorial Health Institute), Rebecca Mardach(Kaiser Permanente), Margaret A. Heisel‐Kurth(Children's Minnesota), Pilar Giraldo(Université Paris-Saclay), Nicola Longo(Center for Human Genetics), Christine M. Eng(Baylor College of Medicine), Paul M. Fernhoff, GM Pastores(New York University), Paul Harmatz(Unknown), Joel Charrow(Northwestern University), William J. Rhead(Children's Hospital of Wisconsin)
Cited by 0
Related Papers
Clinical Whole-Exome Sequencing for the Diagnosis of Mendelian Disorders
|New England Journal of Medicine|2013|2k
Chromosomal Microarray versus Karyotyping for Prenatal Diagnosis
|New England Journal of Medicine|2012|1.4k
Resolution of Disease Phenotypes Resulting from Multilocus Genomic Variation
|New England Journal of Medicine|2016|774
Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
|New England Journal of Medicine|2016|555